Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Patients With Genetic High Cholesterol Disorder
Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Patients With Genetic High Cholesterol Disorder
The Torcetrapib project was terminated on December 2, 2006 due to safety findings.

 To evaluate the efficacy and safety of the lipid drug Torcetrapib/atorvastatin in patients
 with genetically known disorder of extremely high cholesterol
For additional information please call: 1-800-718-1021
Inclusion Criteria:

 -  Diagnosis of Homozygous Familial Hypercholesterolemia

 Exclusion Criteria:

 -  Women who are pregnant or lactating, or planning to become pregnant.

 -  Subjects with a clinically indicated need for statin (HMG-CoA reductase inhibitor)
 therapy other than atorvastatin or other concomitant therapy with known lipid altering
 effects on LDL-C and HDL-C including fibrates and nicotinic acid

 -  Subjects taking any drugs known to be associated with an increased risk of myositis in
 combination with HMG-CoA reductase inhibitors

 -  Subjects with any other medical condition or laboratory abnormality which could affect
 subject safety, preclude evaluationof response, or render unlikely that the subject
 would complete the study